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recombinant human erythropoietin (EPO) -alpha or -beta by intravenous administration (8.5 hours).
However, this might become a disadvantage in the face of rapid withdrawal of the drug against
hemoglobin (Hb) overshoot and/or cycling.
Objective: A ‘‘half-and-half’’ combination therapy of DA and EPO was used to avoid a possible Hb
overshoot due to the full conversion from EPO to DA.
Methods: Thirty-two stable patients receiving HD (13 men, 19 women) and EPO monotherapy were
enrolled and prospectively followed for 9 months. The mean (SD) patient age was 63.2 (11.3) years. The
HD duration was 10.7 (8.2) years. The DA doses (in micrograms) of 1/200 of halves of previous weekly
EPO doses (in international units) were given intravenously on the second HD day of a week. The
remaining half doses of previous weekly EPO doses were dividedly administered intravenously on the
ﬁrst and the third HD days of the week. The target Hb was 11 g/dL.
Results: The ‘‘half-and-half’’ combination with DA and EPO resulted in no episodes of Hb overshoot. The
Hb values did not exceed 13 g/dL throughout the follow-up period. The mean (SD) dose of 3984 (2175)
IU/wk EPO was converted to a combination of 1688 (894) IU/wk EPO and 13.4 (7.9) mg/wk DA at
baseline. Thereafter, the mean (SD) doses became 304 (656) IU/wk EPO and 16.0 (8.4) mg/wk DA at
3 months, and 532 (912) IU/wk and 15.8 (9.0) mg/wk, respectively, at 9 months. The total combination
doses of DA/EPO (as EPO equivalents) were signiﬁcantly reduced to 80% to 84% of the original EPO doses
after 2 months of introduction of the DA/EPO combination.
Conclusions: A ‘‘half-and-half’’ combination therapy may be a safe and easy method to merge DA into
EPO monotherapy without Hb overshoot or dramatic cycling.
& 2013. The Authors. Published by Elsevier Inc.Open access under CC BY license.Introduction
Since the late 1980s, recombinant human erythropoietin (also
known as epoetin [EPO]) has played a critical role in the manage-
ment of renal anemia in patients receiving maintenance dialysis,
resulting in prolonged survival rates and improved quality of life
in addition to decreased need for blood transfusions.1–3 A decadeier Inc.
tsu, MD, Shimamatsu Naika
6, Chikushino City, Fukuoka,
matsu).
Open access under CC BY licelater, darbepoetin-alpha (DA), which has 5 N-linked carbohydrate
chains and 2 added N-linked carbohydrate sites in the primary
sequence (3 N-linked chains) of EPO, was developed for clinical
use with a 3-fold longer mean terminal half-life of 25.3 hours for
intravenous DA compared with 8.5 hours for intravenous EPO.4–6
In fact, DA administered once weekly is as effective and well
tolerated as EPO administered 3 times weekly for the treatment of
anemia in patients not receiving dialysis or patients with chronic
kidney disease who are receiving dialysis.7–10 Its longer terminal
half-life results in reduced dose frequency relative to EPO;
however, this might simultaneously become a disadvantage in
the face of rapid withdrawal of the drug against hemoglobin (Hb)
overshoot and/or cycling.11,12
When DA, which became commercially available in July 2007
in Japan, was introduced to our clinic during December 2007,
halves of weekly EPO doses were converted to DA (‘‘half-and-half’’nse.
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with its full conversion from EPO to DA. This is the ﬁrst report of
combination therapy with DA and EPO in patients receiving
maintenance hemodialysis (HD).Patients and Methods
Although both EPO and DA had been used in clinical practice,
informed consent for this study was obtained by mouth from all
patients enrolled. Thirty-two stable outpatients receiving HD and
EPO monotherapy who had no episodes of bleeding complications
and/or admissions for an antecedent 3 months were selected with
informed consent by word of mouth during December 2007 for
DA/EPO combination therapy and prospectively followed until
September 2008. All patients selected were already stabilized
with intravenous EPO monotherapy for a mean (SD) extended
period of 10.7 (8.2) years before September 2007. HD consisted of
5-hour treatments performed 3 times per week. When DA was
introduced to our clinic during December 2007, halves of weekly
EPO doses were converted to DA by intravenous injection. The
drug preparations available to our clinic were as follows: 10, 20,
and 40 mg DA (Nesp; Kyowa Hakko Kirin Co Ltd, Tokyo, Japan) and
750, and 1500 IU EPO (Epogin; Chugai Pharmaceutical Co Ltd,
Tokyo, Japan). Preparations of DA close to the doses (in micro-
grams) of 1/200 5,7–9 of halves of weekly EPO doses (in interna-
tional units) were chosen from among the lineups and given
intravenously on the second HD day of each week. The remaining
half doses of EPO were divided and administered intravenously on
the ﬁrst and the third HD days of the week (Figure 1). The target
Hb level was 11 g/dL. After introduction of DA combined with
EPO, EPO was eliminated when the Hb levels rose to 412 g/dL. In
cases of unchanged Hb levels DA doses were increased. When the
Hb levels decreased to 10 g/dL after elimination of EPO, EPO was
added again to augment the DA treatment (Figure 1).
Intravenous iron supplementation (ferric oxide, saccharated)
(Fesin; Nichi-Iko Co. Ltd, Toyama, Japan) was also administered.
When serum ferritin levels fell to o100 ng/mL, 40 mg iron was
administered intravenously once a week. Once serum ferritin
levels reached 4100 ng/mL, 40 mg iron was given intravenously
twice a month and adjusted quarterly (during March, June,
September, and December) according to serum ferritin measure-
ments.13,14 When the quarterly serum ferritin values exceeded
300 ng/mL the frequency of intravenous iron administration was
decreased and when they reached 500 ng/mL, iron supplementa-
tion was discontinued. A complete blood count was performedHemodialysis (HD) day
of a week
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Figure 1. Schematic image of ‘‘half-and-half’’ combination therapy with darbepoetin
micrograms) of 1/200 of halves of weekly EPO doses (in international units) were chose
the week. The remaining half doses of EPO were divided and given intravenously ontwice monthly. The serum ferritin concentration and the total
iron-binding capacity were determined quarterly, and the serum
iron concentration was measured monthly along with the other
routine general blood tests. The transferrin saturation (TSAT) was
calculated using the following formula: (serum iron concentra-
tion/total iron-binding capacity)100%. All data are presented as
mean (SD). Student t test (paired and unpaired) was applied for
statistical analysis. Differences were considered to be statistically
signiﬁcant at P values o0.05. Data from December 2007 were
used as baseline values.Results
The mean (SD) age of patients (13 men, 19 women) was 63.2
(11.3) years. The mean (SD) HD duration was 10.7 (8.2) years.
The underlying renal diseases were chronic glomerulonephritis
in 17 patients, diabetic nephropathy in 7 patients, hypertensive
nephrosclerosis in 3 patients, chronic pyelonephritis in
2 patients, polycystic kidney disease in 2 patients, and Alport
syndrome in 1 patient.
As shown in the Table, before and after converting the EPO
monotherapy to the ‘‘half-and-half’’ combination therapy of DA
and EPO, mean Hb levels remained unchanged at around
11 g/dL of the Hb target during the study period. However,
the Hb levels in November 2007 and in February, March, and
September 2008 were signiﬁcantly higher than that observed in
December 2007 (baseline). During the combination therapy
there were no episodes of Hb overshooting (43 g/dL11,12). As
shown in Figure 2, the actual Hb values did not exceed 13 g/dL
throughout the follow-up period. The mean (SD) dose of EPO,
which was 3984 (2175) IU/wk in November 2007, was con-
verted to the combination therapy with 1688 (894) IU/wk EPO
and 13.4 (7.9) mg/wk DA in December 2007. Thereafter, the
mean doses of the combination became 304 (656) IU/wk EPO
and 16.0 (8.4) mg/wk DA in March 2008, and 532 (912) IU/wk
and 15.8 (9.0) mg/wk (n ¼ 31), respectively, in September 2008.
The total doses of DA/EPO as EPO equivalents were signiﬁcantly
reduced to 80% to 84% of baseline EPO dose after February 2008
(see Table). Three months after the combination therapy,
approximately 70% of patients were receiving DA alone and
30% of patients were receiving combination therapy (Figure 3).
Mean (SD) serum ferritin concentration and TSAT did not
signiﬁcantly change throughout the study period: 237 (82)
ng/mL serum ferritin concentration and 31.0% (11.3%) of TSAT
in September 2007, 253 (83) ng/dL serum ferritin concentrationO
alf combination therapy
r 2007)
EPO
O
A
EPO
+3
Study month
+6 +9
(DA) and epoetin (EPO). Preparations (see the text) of DA close to the doses (in
n from the lineups and given intravenously on the second hemodialysis (HD) day of
the ﬁrst and the third HD days of the week.
Table
The serial changes of epoetin and darbepoetin doses (including total doses as epoetin equivalents), hemoglobin value, serum ferritin concentration, and transferrin
saturation (TSAT) in 32 maintenance hemodialysis patients before and after the introduction of darbepoetin in December 2007.*
2007 2008
September October November December January February March June September
Study Month
3 2 1 0 (Baseline) þ1 þ2 þ3 þ6 þ9
n 32 32 32 32 32 32 32 31y 31y
Epoetin beta (IU/wk) 4148 (1797) 4148 (2007) 3984 (2175) 1688 (894) 1172 (951) 445 (734) 304 (656) 339 (720) 532 (912)y
Darbepoetin alpha (mg/wk) 0 0 0 13.4 (7.9) 16.7 (9.1) 15.8 (8.5) 16.0 (8.4) 16.6 (8.1) 15.8 (9.0)
Total doses as epoetin
equivalent (IU/wk)z
4148 (1797) 4148 (2007) 3984 (2175) 4375 (2136) 4516 (2300) 3602 (1831)y 3510 (1753)y 3661 (2030)J 3694 (2400)y
Hemoglobin (g/dL) 10.8 (0.6) 11.0 (0.7) 11.0 (0.8)y 10.7 (0.7) 10.8 (0.6) 11.2 (0.7)y 11.1 (0.7)y 10.8 (0.7) 11.0 (0.7)y
Serum ferritin (ng/mL) 237 (82) Not done Not done 253 (83) Not done Not done 232 (96) 227 (88) 239 (109)
TSAT (%) 31.0 (113) Not done Not done 30.5 (10.5) Not done Not done 31.6 (16.6) 30.8 (13.0) 31 (12.5)
n Data are expressed as mean (SD).
y The data deﬁcit (n ¼ 31) in June and September 2008 resulted from an admission of a male patient (aged 77 years) who had an accidental contusion of the head in
the bathroom accompanied by intracranial bleeding.
z Total doses as epoetin equivalents are calculated using the formula [epoetin dose þ (200  darbepoetin dose)].
y P o0.05.
J P o0.01 (against the baseline data of December 2007).
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‘‘half-and-half’’ combination), and 239 (109) ng/mL serum
ferritin concentration and 33.1% (12.5%)of TSAT (n ¼ 31) in
September 2008.Discussion
Despite the irreplaceable effects of EPO or DA on anemia
management in patients with CKD,1–3,7–9 recent large-scale ran-
domized controlled trials15–18 strongly suggested harmful effects
of higher doses of EPO or DA per se as well as higher Hb levels
close to normal (413 g/dL). Our approach using ‘‘half-and-half’’
combination of DA and EPO may be a safe and easy way to
introduce DA without overshooting Hb levels beyond the ranges
recommended.19,20 In the study for comparing DA with EPO on
anemia management in patients with chronic renal failure not yet
on dialysis reported by the European/Australian Novel Erythro-
poiesis Stimulating Protein Study Group,7 Hb overshooting 414
g/dL developed in 24% of patients treated with DA and in
35% of patients treated with EPO. The combination of
DA/EPO therapy proposed in our study might become a solutionigure 2. Serial changes in hemoglobin (Hb) values in 32 maintenance hemodia-
ysis (HD) patients before and after the initiation of ‘‘half-and-half’’ combination
herapy with darbepoetin (DA) and epoetin (EPO). During the ﬁrst 3 months of the
ransition from EPO monotherapy to ‘‘half-and-half’’ combination therapy of DA/
PO, only a few data exceeded Hb level of 12 g/dL. All Hb levels were o13 g/dL.
F
i
Eof potential concern for Hb overshooting on EPO or DA
monotherapy.
Although the conversion ratio from EPO to DA was originally
recommended to be 1:200 (1 mg DA ¼ 200 IU EPO),5,7–9 revised
ratios of 1:250 to 350 have recently been reported.6,21–23 In our
study, in which the original conversion ratio of 1:200 was
adopted, the virtual conversion ratio became 1:400 because the
half dose of EPO was converted to DA. The approach proposed
here for initiation of DA may be safe and easy for those who are
not familiar with the drug and prefer to avoid the drastic
conversion from EPO to DA. In our study, although the total doses
(as the equivalent of EPO) of DA with EPO were reduced to
between 80% and 84% of the baseline EPO dose during the period
of EPO monotherapy, the ﬁnal mean (SD) doses of the DA/EPO
combination therapy were 15.8 (9.0) mg/wk DA and 532 (912)
IU/wk EPO versus the baseline weekly doses of 3984 (2175) IU/wk
having resulted in the consequent conversion ratio of 1:220 (see
the Table). Interestingly, Bock et al22 reported that although the
equimolar 1:200 conversion ratio was appropriate for lower
EPO doses (o5000 IU/wk) DA dose for patients converting
from Z5000 IU/wk EPO was more likely to follow a 1:250 to
1:350 conversion rule. Our DA/EPO combination method may be,100
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therapy Z5000 IU/wk.
Our study also showed that the small lineups of 10, 20, and 40
mg DA and 750, and 1500 IU EPO were enough to carry out the
‘‘half-and-half’’ combination therapy. Further, by designating the
days of a week to apply the preparations (the second HD day of a
week for DA and the ﬁrst and third HD days of a week for EPO), no
staff members made injection mistakes during the study period
(Figure 1).
In addition, iron indices of serum ferritin concentration and
TSAT were not changed after introduction of DA in our study,
consistent with the results from other studies.9,23 A longer period
of observation will, however, be needed to verify whether or not
the iron requirement is changed by introduction of DA.Conclusions
A ‘‘half-and-half’’ combination therapy may be a safe and easy
method to merge DA into EPO monotherapy without a concern
about an overshoot in Hb. Further, its long-term effect on anemia
management in HD patients is worth testing.Acknowledgments
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